The study, “Navigating Compounded Semaglutide: What Health Care Providers Need to Know,” published in the September 2025 issue of The American Journal of Managed Care® (AJMC®), provides a comprehensive evaluation of the safety, efficacy, and regulatory considerations surrounding unapproved versions of semaglutide, advising providers on how to safely guide patients during the medication shortage. Forbes references these findings to explain the origin of the alternative weight-loss market, citing the study to illustrate how nationwide drug shortages and insurance barriers have driven suppliers to sell compounded formulations both legally and illegally.
The study, "Regulating Private Equity in Health Care: A Strategic Policy Agenda," published in the May 2026 issue of AJMC, outlines a comprehensive policy framework designed to address the rapid expansion of private equity in health care, focusing on solutions like strengthening corporate practice of medicine laws and increasing transparency around physician practice acquisitions. Becker's ASC Review references this strategic agenda to contextualize recent legislative efforts in states like California, Indiana, and Minnesota, illustrating how local lawmakers are actively adopting these recommended regulatory frameworks to curb the perceived risks of institutional capital in medicine.
The study, “Musculoskeletal Quality Collaborative Improves Value-Based Health Care Delivery Across Hospital System,” published in the June 2026 issue of AJMC, demonstrates that implementing a multidisciplinary, physician-led musculoskeletal quality collaborative across a major health system could reduce use of high-cost consumables and maintain low infection rates. Becker's Spine Review references these findings to highlight how the initiative successfully identified $800,000 in surgical supply savings, using the study's data to show that coordinating care across departments can improve value-based health care delivery without compromising patient outcomes.
The study, “Persistence of Provider Directory Inaccuracies After the No Surprises Act,” published in the November 2024 issue of AJMC, reveals that despite federal mandates under the No Surprises Act requiring insurers to update directory information every 90 days, roughly 40% of identified provider listing inaccuracies persisted for an average of 540 days. Hawai'i Free Press references these findings to support its report on local "ghost networks," pointing to the study's data as national evidence that insurance plans lack the structural incentives to maintain accurate directories, which ultimately leaves up to 69% of Hawaii's listed health care providers functionally unavailable to patients.
The systematic review, “Prescription Drug Prior Authorization: Costs to Pharmacies and Physicians,” in the June 2026 issue of AJMC, quantifies the extensive administrative burdens of insurance mandates, demonstrating that completing a single prescription prior authorization can take up to 64 minutes and cost providers more than $60. BenefitsPRO references these findings to underscore the expanding financial and operational constraints placed on health care providers, using the study's data to highlight how these delays disrupt patient care.
The article, “Alarming Rise in Liver Disease Amid Global Fatty Liver Day 2025,” on AJMC.com, the website of AJMC, highlights the global escalation of metabolic dysfunction–associated steatotic liver disease, emphasizing that the condition is often asymptomatic and underdiagnosed until it reaches advanced stages. GE Healthcare references these alarming epidemiological trends to underscore the critical need for scalable diagnostic tools, positioning their specialized ultrasound technologies as an accessible solution for the early detection and management of fatty liver disease.
The article published on AJMC.com, “Drug Overdoses Drop by 14% in 2025 Compared With Previous Year,” reports on encouraging public health data showing a significant 14% year-over-year decline in US drug overdose fatalities in 2025, a shift largely attributed to expanded harm reduction strategies and the broader availability of addiction treatment services. GBH references these national statistics to highlight local progress in Massachusetts, contrasting the country's overall 14% drop with the state's own remarkable achievement of doubling the national average to significantly lower local overdose deaths.
